AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22974389 — intervention group
Group type: COMPARATOR
Intervention: Fellow eye (control)
Number of subjects: 20
Study 19144727 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 chews
Number of subjects: 13
Study 19144727 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 chews
Number of subjects: 13
Study 19144727 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 chews
Number of subjects: 13
Study 17694802 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ketamine 0.3 mg/kg intravenously before the start of operation
Number of subjects: 90
Study 17694802 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ketamine 0.3 mg/kg intravenously at the end of operation
Number of subjects: 90
Study 17694802 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline i.v. before the incision
Number of subjects: 90
Study 15082128 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care + pain booklet
Number of subjects: 406
Study 15082128 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 406
Study 11549529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate-salmeterol combination therapy (FSC) administered twice daily (100 microg of fluticasone propionate and 50 microg of salmeterol)
Number of subjects: 423
Study 11549529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate-salmeterol combination therapy (FSC) administered twice daily
Number of subjects: 423
Study 11549529 — intervention group
Group type: COMPARATOR
Intervention: Montelukast (10 mg once daily)
Number of subjects: 423
Study 9668941 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral marital therapy (BMT)
Number of subjects: 36
Study 9668941 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactional couples therapy group
Number of subjects: 36
Study 9668941 — intervention group
Group type: COMPARATOR
Intervention: No-marital-treatment control group
Number of subjects: 36
Study 8062318 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release ketoprofen 200 mg once daily for 3 weeks
Number of subjects: 60
Study 8062318 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg once daily for 3 weeks
Number of subjects: 60
Study 31174236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab and bendamustine (arm A)
Number of subjects: 128
Study 31174236 — intervention group
Group type: COMPARATOR
Intervention: Ofatumumab, bendamustine, and bortezomib (arm B)
Number of subjects: 128
Study 27918931 — intervention group
Group type: EXPERIMENTAL
Intervention: Encourage Autonomous Self‐Enrichment program for 12 weeks
Number of subjects: 65
Study 27918931 — intervention group
Group type: COMPARATOR
Intervention: Standard education provided by nurses
Number of subjects: 65
Study 25447626 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan and nateglinide
Number of subjects: 9306
Study 25447626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9306
Study 23132842 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys (n=54)
Number of subjects: 116
Study 23132842 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls (n=62)
Number of subjects: 116
Study 22018765 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine cream
Number of subjects: 39
Study 22018765 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 39
Study 18485819 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate-ganglion block
Number of subjects: 13
Study 16936546 — intervention group
Group type: EXPERIMENTAL
Intervention: ArteFill
Number of subjects: 251
Study 16936546 — intervention group
Group type: COMPARATOR
Intervention: Bovine collagen dermal filler
Number of subjects: 251
Study 14513451 — intervention group
Group type: EXPERIMENTAL
Intervention: 90/90 pillow
Number of subjects: 40
Study 14513451 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 40
Study 11213545 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.2 microgram/kg i.v. as premedication and 0.15 microgram/kg during maintenance)
Number of subjects: 50
Study 11213545 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (2.0 micrograms/kg as premedication and 1.5 micrograms/kg during maintenance)
Number of subjects: 50
Study 11213545 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 50
Study 11213545 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 50
Study 8936893 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support intervention for mothers of children with JRA over 15 months
Number of subjects: 0
Study 8247819 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with an inspiratory pressure load equal to 30% of PImax
Number of subjects: 67
Study 8247819 — intervention group
Group type: COMPARATOR
Intervention: Sham training with a light inspiratory pressure load
Number of subjects: 67
Study 3546779 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diltiazem, 180 mg/day
Number of subjects: 32
Study 3546779 — intervention group
Group type: COMPARATOR
Intervention: Oral verapamil, 240 mg/day
Number of subjects: 32
Study 29484548 — intervention group
Group type: EXPERIMENTAL
Intervention: Active periodontal therapy (subgingival debridement); systemic antibiotics prescribed if Aggregatibacter actinomycetemcomitans was detected (10 AgP, 8 ChP); flap surgery if required.
Number of subjects: 42
Study 27788686 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-assisted reduction to stop (EARS) smoking intervention
Number of subjects: 99
Study 24787491 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Self-Administered 24-hour Recall (ASA24)
Number of subjects: 81
Study 24787491 — intervention group
Group type: COMPARATOR
Intervention: Interviewer-administered Automated Multiple-Pass Method (AMPM)
Number of subjects: 81
Study 22394647 — intervention group
Group type: EXPERIMENTAL
Intervention: E-info geneca (pre-visit educational website)
Number of subjects: 197
Study 22394647 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 197
Study 21095264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous epoetin α (up to 60,000 IU)
Number of subjects: 250
Study 21095264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 18996930 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients supplementation
Number of subjects: 5828
Study 18996930 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron with folic acid supplementation
Number of subjects: 5828
Study 18996930 — intervention group
Group type: COMPARATOR
Intervention: Folic acid supplementation
Number of subjects: 5828
Study 15951327 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. tramadol 1.5 mg kg(‐1) and i.v. ketorolac 0.3 mg kg(‐1)
Number of subjects: 46
Study 15951327 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 46
Study 12460784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 5 g/m(2) over 24 h (5 g/m(2)/1 day), every 3 weeks
Number of subjects: 182
Study 12460784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 3 g/m(2) per day over 4 h on three consecutive days (3 g/m(2)/3 days), every 3 weeks
Number of subjects: 182
Study 12460784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 5 g/m(2) over 24 h (5 g/m(2)/1 day), second-line treatment
Number of subjects: 182
Study 12460784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 3 g/m(2) per day over 4 h on three consecutive days (3 g/m(2)/3 days), second-line treatment
Number of subjects: 182
Study 12460784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 5 g/m(2) over 24 h (5 g/m(2)/1 day)
Number of subjects: 182
Study 12460784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 3 g/m(2) per day over 4 h on three consecutive days (3 g/m(2)/3 days)
Number of subjects: 182
Study 10393490 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 0
Study 10393490 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews and meta-analyses
Number of subjects: 0
Study 7489439 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol plus ketorolac
Number of subjects: 0
Study 7489439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Number of subjects: 0
Study 7489439 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol alone
Number of subjects: 0
Study 7489439 — intervention group
Group type: COMPARATOR
Intervention: Control group (no morphine)
Number of subjects: 0
Study 1952133 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand-dose PCEA (3 mL every 10 min without restriction)
Number of subjects: 40
Study 1952133 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI) (0.125% bupivacaine with fentanyl at 12 mL/h)
Number of subjects: 40
Study 1952133 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand-dose PCEA
Number of subjects: 40
Study 1952133 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI)
Number of subjects: 40
Study 7030837 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone, 40 mg given orally on alternate days
Number of subjects: 24
Study 7030837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29745688 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation (measured by DERS)
Number of subjects: 290
Study 29674314 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app-based educational program (4-week access)
Number of subjects: 17
Study 27390150 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-494 3 mg twice daily
Number of subjects: 300
Study 27390150 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-494 6 mg twice daily
Number of subjects: 300
Study 27390150 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-494 12 mg twice daily
Number of subjects: 300
Study 27390150 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-494 18 mg twice daily
Number of subjects: 300
Study 27390150 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-494 24 mg once daily
Number of subjects: 300
Study 27390150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 24861892 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-T2DM diagnosis activity levels
Number of subjects: 2816
Study 24861892 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted post-T2DM diagnosis activity levels
Number of subjects: 2816
Study 23095351 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual care
Number of subjects: 233
Study 23095351 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 233
Study 23095351 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for severe IBS cases (Symptom Severity Score over 300)
Number of subjects: 233
Study 20214462 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus Docobo HealthHUB monitors at home for 26 weeks followed by 26 weeks standard care (Tm Group)
Number of subjects: 40
Study 20214462 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Controls) for 52 weeks
Number of subjects: 40
Study 17941871 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day plus hypolipaemic diet
Number of subjects: 204
Study 17941871 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus hypolipaemic diet
Number of subjects: 204
Study 15982813 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (plasma concentration 70ng/ml)
Number of subjects: 16
Study 15982813 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine high dose (plasma concentration 30ng/ml)
Number of subjects: 16
Study 15982813 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine low dose (plasma concentration 15ng/ml)
Number of subjects: 16
Study 15982813 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (active placebo, 20microg/kg for 10min)
Number of subjects: 16
Study 15982813 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs tested
Number of subjects: 16
Study 12813380 — intervention group
Group type: EXPERIMENTAL
Intervention: Redon drains (RD)
Number of subjects: 40
Study 12813380 — intervention group
Group type: COMPARATOR
Intervention: Chest tubes (CT)
Number of subjects: 40
Study 11263274 — intervention group
Group type: EXPERIMENTAL
Intervention: Xin Mai Tong Capsule
Number of subjects: 40
Study 11263274 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 11263274 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Xin Mai Tong group and Control group
Number of subjects: 40
Study 8964881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8964881 — intervention group
Group type: EXPERIMENTAL
Intervention: 24,25(OH)2 D3
Number of subjects: 15
Study 1996531 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE grafts for initial femoropopliteal reconstruction
Number of subjects: 0
Study 1996531 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous saphenous vein for secondary repair
Number of subjects: 0
Study 1996531 — intervention group
Group type: COMPARATOR
Intervention: PTFE grafts for initial reconstruction
Number of subjects: 0
Study 1996531 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein for initial reconstruction
Number of subjects: 0
Study 6480127 — intervention group
Group type: EXPERIMENTAL
Intervention: Toluene at 100 ppm
Number of subjects: 144
Study 6480127 — intervention group
Group type: EXPERIMENTAL
Intervention: MEK at 200 ppm
Number of subjects: 144
Study 6480127 — intervention group
Group type: EXPERIMENTAL
Intervention: Toluene (50 ppm) and MEK (100 ppm) in combination
Number of subjects: 144
Study 6480127 — intervention group
Group type: COMPARATOR
Intervention: Ethanol at 0.08%
Number of subjects: 144
Study 31783777 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing of the palate and immersion of the prosthesis in 0.15% triclosan solution
Number of subjects: 100
Study 31783777 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing of the palate and immersion of the prosthesis in lactose monohydrate
Number of subjects: 100
Study 31783777 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing the palate with citric acid and immersing the prosthesis in lactose monohydrate
Number of subjects: 100
Study 31783777 — intervention group
Group type: COMPARATOR
Intervention: Brushing of the palate and immersion of the prosthesis in 0.25% sodium hypochlorite solution
Number of subjects: 100
Study 29187474 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 114
Study 29187474 — intervention group
Group type: EXPERIMENTAL
Intervention: Minicholecystectomy (MC)
Number of subjects: 114
Study 29187474 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation of the gallbladder wall (IGW)
Number of subjects: 114
Study 29187474 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IGW with plasma CRP levels
Number of subjects: 114
Study 29187474 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IGW with plasma GPX1 levels
Number of subjects: 114
Study 27721534 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg once a day for 12 weeks
Number of subjects: 60
Study 27721534 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 24043482 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (n=31)
Number of subjects: 86
Study 24043482 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Portland cement (n=29)
Number of subjects: 86
Study 24043482 — intervention group
Group type: EXPERIMENTAL
Intervention: White MTA (n=26)
Number of subjects: 86
Study 22869566 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of liposomal amphotericin B/kg/day
Number of subjects: 30
Study 22869566 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of liposomal amphotericin B/kg at time zero, followed by 5 mg/kg at 48 and 120 h
Number of subjects: 30
Study 19713258 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 150
Study 19713258 — intervention group
Group type: EXPERIMENTAL
Intervention: Storz V‐Mac
Number of subjects: 150
Study 19713258 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath
Number of subjects: 150
Study 17208102 — intervention group
Group type: COMPARATOR
Intervention: Conventional pendulum appliances
Number of subjects: 30
Study 17208102 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal osseointegrated implants combined with pendulum springs
Number of subjects: 30
Study 17208102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intergroup comparisons
Number of subjects: 30
Study 15140263 — intervention group
Group type: EXPERIMENTAL
Intervention: PDM training approximately four weeks prior to the SPE
Number of subjects: 0
Study 15140263 — intervention group
Group type: EXPERIMENTAL
Intervention: PDM training approximately 12 weeks prior to the SPE
Number of subjects: 0
Study 15140263 — intervention group
Group type: COMPARATOR
Intervention: No PDM training
Number of subjects: 0
Study 10913921 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral fracture group (31 women and 16 men)
Number of subjects: 80
Study 10913921 — intervention group
Group type: COMPARATOR
Intervention: Non-fracture group (22 women and 11 men)
Number of subjects: 80
Study 10913921 — intervention group
Group type: EXPERIMENTAL
Intervention: Both fracture and non-fracture groups
Number of subjects: 80
Study 8757200 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12
Study 8757200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1582124 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-releasing nicardipine (20 mg two times daily)
Number of subjects: 21
Study 1582124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2417476 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (Ch-XRT) - methotrexate, bleomycin, cisplatin with split-course irradiation (2,000 rad/10 preop., 4,000 rad/20 postop.)
Number of subjects: 79
Study 2417476 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (surgery and/or irradiation alone) - includes randomized control (RC) and concomitantly-treated (CC) patients
Number of subjects: 79
Study 30756411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 3 mL/kg 20% albumin over 30 minutes
Number of subjects: 30
Study 29261824 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline tartrate, 1 mg twice daily for 16 weeks
Number of subjects: 131
Study 29261824 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline tartrate
Number of subjects: 131
Study 26688003 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rituximab (two 375-mg/m2 infusions)
Number of subjects: 45
Study 26688003 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose rituximab (two 1000-mg infusions)
Number of subjects: 45
Study 26688003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 22821022 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning
Number of subjects: 0
Study 22821022 — intervention group
Group type: COMPARATOR
Intervention: Lecture learning
Number of subjects: 0
Study 19924007 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance plus whole-body vibration (SQTV)
Number of subjects: 30
Study 19924007 — intervention group
Group type: COMPARATOR
Intervention: Resistance training only (SQT)
Number of subjects: 30
Study 18194413 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic Antithrombin Replacement in Kids with ALL treated with L‐Asparaginase (PARKAA) study
Number of subjects: 54
Study 18194413 — intervention group
Group type: COMPARATOR
Intervention: Unselected childhood ALL survivors
Number of subjects: 54
Study 15672001 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol cypionate
Number of subjects: 123
Study 15672001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 12773303 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion for 60 min
Number of subjects: 8
Study 10822909 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10
Number of subjects: 23
Study 10822909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 8837409 — intervention group
Group type: EXPERIMENTAL
Intervention: Characters identified and tested verbally
Number of subjects: 80
Study 8837409 — intervention group
Group type: EXPERIMENTAL
Intervention: Characters identified and tested visually
Number of subjects: 80
Study 8837409 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined characters
Number of subjects: 80
Study 8837409 — intervention group
Group type: EXPERIMENTAL
Intervention: Seen characters
Number of subjects: 80
Study 1614233 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacists' consultations
Number of subjects: 236
Study 2860931 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 24
Study 2860931 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 20 mg
Number of subjects: 24
Study 2860931 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 40 mg
Number of subjects: 24
Study 30418593 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine (DHA-PQ)
Number of subjects: 599
Study 30418593 — intervention group
Group type: COMPARATOR
Intervention: Artemether-Lumefantrine (AL)
Number of subjects: 599
Study 30122620 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin at 1.8 mg/kg with gemcitabine 1000 mg/m2
Number of subjects: 42
Study 27605258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg once daily
Number of subjects: 325
Study 27605258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 15 mg once daily
Number of subjects: 325
Study 27605258 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 325
Study 24562349 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) + tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 741
Study 24562349 — intervention group
Group type: EXPERIMENTAL
Intervention: nevirapine (NVP) + tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 741
Study 22009525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin (CIP IV) 300 mg b.i.d.
Number of subjects: 205
Study 22009525 — intervention group
Group type: COMPARATOR
Intervention: Intravenous meropenem (MEM IV) 500 mg b.i.d.
Number of subjects: 205